(Finance) – Pharmacosmosa company active in the Health, Pharma & Beauty, Pet and Digital Health sectors, listed on the Euronext Growth Milan market of the Italian Stock Exchange, recorded total revenues of the Group for the first nine months of 2024 equal to approximately 47 million Euros, down by 10.6% compared to the same period of the previous year, impacted by the reduction of the B2B channel for 5.7 million Euros (-34.5 % YoY). “The Group – we read in a note – continues to focus its efforts on the channels that have consistently shown greater profitability and is in fact driven by the segment Retail (+3.6% YoY), which is increasingly predominant compared to B2B. The weight of the B2B channel is equal to 23% of total revenues, a further reduction compared to 31% in the same period of the previous year”.
The growth of retail channel is driven by the continuous progression of BauCosmesi.it growing by over 170% year on year, reaching approximately 2.5 million euros in the nine months. Farmacosmo.it grew in the quarter by almost 5% compared to the same period of the previous year, recovering the limited reduction in turnover in the first half of the year, reaching around 25.7 million euros in the nine months but with a higher margin on sales. The revenues of ProfumeriaWeb.com they stand at approximately 2.7 million euros, in line with the same period of the previous year.
Finally, the revenues of Pharmasì.it they stand at approximately 2.8 million Euros, a reduction of 18% compared to the same period of the previous year by virtue of the strategic choice aimed at greater margins on sales, a choice already manifested in terms of EBITDA in the first half of the year.
The EBITDA of De Leo Pharmacy presents a positive value of Euro 133 thousand in the first half of 2024 compared to a negative value of Euro 14 thousand in the first half of 2023.
“The third quarter also confirms the trajectory of the first part of the year: growth of the retail channel thanks to the development of the proprietary portals and the numerous synergies put in place, strategic reduction of the B2B channel in order to preserve the profitability target, strengthening of the Digital Health thanks to the continuous development of numerous initiatives implemented with our ContactU telepsychology platform. We continue to work on the consolidation of the retail channel and the Digital Health channel, continuing to favor revenues with satisfactory margins makes us look at the last part of the year with great positivity”, he commented Fabio de ConcilioPresident and CEO of Farmacosmo.